BerGenBio

Director's Dealing • Jun 8, 2023

Mandatory notification of trade by Primary Insiders and close associates

Mandatory notification of trade by Primary Insiders and close associates

Reference is made to the stock exchange announcement published by BerGenBio ASA

(the "Company") on 30 May 2023, regarding the commencement of the subscription

period in the rights issue (the "Rights Issue") and the receipt of subscription

rights in the Rights Issue by certain primary insiders and certain close

associates of primary insiders of the Company.

Today, the Company has been informed that Martin Olin, CEO of the Company, on 5

June 2023, exercised 1,046,125 subscription rights in the Rights Issue,

entitling Martin Olin to be allocated 1,046,125 offer shares in the Rights Issue

at a price per offer share of NOK 0.10, subject to the Rights Issue being

completed.

Please see further details about the transactions in the attached forms.

This information is subject to the disclosure requirements pursuant to article

19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian

Securities Trading Act.